Melanoma primary prevention

Mortality for melanoma is the highest of all the skin cancers. It is estimated that about 8,000 individuals will die of melanoma in 2005. The mortality rate from melanoma appears to have stabilized and possibly declined in recent years in Australia, the United States, and Europe. The stabilization of mortality rates appears to be in part due to efforts at both primary and secondary prevention of melanoma. 

The relapse rates of resected deep primary, or regional lymph node metastatic melanoma could be reduced by post-operative therapy with lENa (10-15 % reduction), or with viral oncolysate vaccines especially, NDV oncolysates were effective (decades long durable remissions induced). Preventively, the Morton allogeneic melanoma cell-BCG Canvax vaccines did not work in prospectively designed clinical trials, but it induces immune reactions and reduces circulating tumor cell numbers. Oncolytic viruses directly injected into melanoma tumors induce partial remissions. ... 

---